A Replication-Competent, Neuronal Spread-Defective, Live Attenuated Herpes Simplex Virus Type 1 Vaccine
- 1 September 2008
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 82 (17), 8431-8441
- https://doi.org/10.1128/jvi.00551-08
Abstract
Herpes simplex virus type 1 (HSV-1) produces oral lesions, encephalitis, keratitis, and severe infections in the immunocompromised host. HSV-1 is almost as common as HSV-2 in causing first episodes of genital herpes, a disease that is associated with an increased risk of human immunodeficiency virus acquisition and transmission. No approved vaccines are currently available to protect against HSV-1 or HSV-2 infection. We developed a novel HSV vaccine strategy that uses a replication-competent strain of HSV-1, NS-gEnull, which has a defect in anterograde and retrograde directional spread and cell-to-cell spread. Following scratch inoculation on the mouse flank, NS-gEnull replicated at the site of inoculation without causing disease. Importantly, the vaccine strain was not isolated from dorsal root ganglia (DRG). We used the flank model to challenge vaccinated mice and demonstrated that NS-gEnull was highly protective against wild-type HSV-1. The challenge virus replicated to low titers at the site of inoculation; therefore, the vaccine strain did not provide sterilizing immunity. Nevertheless, challenge by HSV-1 or HSV-2 resulted in less-severe disease at the inoculation site, and vaccinated mice were totally protected against zosteriform disease and death. After HSV-1 challenge, latent virus was recovered by DRG explant cocultures from <10% of vaccinated mice compared with 100% of mock-vaccinated mice. The vaccine provided protection against disease and death after intravaginal challenge and markedly lowered the titers of the challenge virus in the vagina. Therefore, the HSV-1 gEnull strain is an excellent candidate for further vaccine development.Keywords
This publication has 54 references indexed in Scilit:
- An HSV-1 gD mutant virus as an entry-impaired live virus vaccineVaccine, 2008
- Efficacy of Recombinant Herpes Simplex Virus 1 Glycoprotein D Candidate Vaccines in MiceActa Microbiologica Et Immunologica Hungarica, 2006
- Genital HSV-1 infectionsSexually Transmitted Infections, 2006
- Herpes Simplex Virus Type 1 and 2 Glycoprotein C Prevents Complement-Mediated Neutralization Induced by Natural Immunoglobulin M AntibodyJournal of Virology, 2006
- A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older AdultsNew England Journal of Medicine, 2005
- Safety and Immunogenicity of Glycoprotein D--Adjuvant Genital Herpes VaccineClinical Infectious Diseases, 2005
- Comparative Efficacy and Immunogenicity of Replication-Defective, Recombinant Glycoprotein, and DNA Vaccines for Herpes Simplex Virus 2 Infections in Mice and Guinea PigsJournal of Virology, 2005
- A Prospective Study of New Infections with Herpes Simplex Virus Type 1 and Type 2New England Journal of Medicine, 1999
- Efficacy of the Herpes Simplex Virus Types 1 and 2 Mutant Viruses to Confer Protection against Zosteriform Spread in MiceViral Immunology, 1993
- Replacement of Glycoprotein B Gene Sequences in Herpes Simplex Virus Type 1 Strain ANG by Corresponding Sequences of the Strain KOS Causes Changes of Plaque Morphology and NeuropathogenicityJournal of General Virology, 1987